BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33803522)

  • 1. Supplemental
    Bicu F; Rink JS; Froelich MF; Cyran CC; Rübenthaler J; Birgin E; Röhrich M; Tollens F
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis.
    Burian E; Palla B; Callahan N; Pyka T; Wolff C; von Schacky CE; Schmid A; Froelich MF; Rübenthaler J; Makowski MR; Gassert FG
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3870-3877. PubMed ID: 35606526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of
    Regenet N; Sauvanet A; Muscari F; Meunier B; Mariette C; Adham M; Moutardier V; Delpero JR; Regimbeau JM; Pessaux P; Paye F; Sa Cunha A; Ansquer C
    J Visc Surg; 2020 Oct; 157(5):387-394. PubMed ID: 32005594
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Gassert FG; Rübenthaler J; Cyran CC; Rink JS; Schwarze V; Luitjens J; Gassert FT; Makowski MR; Schoenberg SO; Mayerhoefer ME; Tamandl D; Froelich MF
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3268-3276. PubMed ID: 33686457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of 18-FDG PET/CT in Detecting Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Yamashita YI; Okabe H; Hayashi H; Imai K; Nakagawa S; Nakao Y; Yusa T; Itoyama R; Yama T; Umesaki N; Arima K; Miyata T; Chikamoto A; Baba H
    Anticancer Res; 2019 May; 39(5):2493-2499. PubMed ID: 31092444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the cost-effectiveness of [
    Tew M; Douglas AP; Szer J; Bajel A; Harrison SJ; Tio SY; Worth LJ; Hicks RJ; Ritchie D; Slavin MA; Thursky KA; Dalziel K
    Cancer Imaging; 2023 Dec; 23(1):119. PubMed ID: 38102639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm.
    Hong HS; Yun M; Cho A; Choi JY; Kim MJ; Kim KW; Choi YJ; Lee JD
    Clin Nucl Med; 2010 Oct; 35(10):776-9. PubMed ID: 20838285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
    Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
    Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-Up 18F-FDG PET/CT versus Contrast-Enhanced CT after Ablation of Liver Metastases of Colorectal Carcinoma-A Cost-Effectiveness Analysis.
    Schnitzer ML; Froelich MF; Gassert FG; Huber T; Gresser E; Schwarze V; Nörenberg D; Todica A; Rübenthaler J
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Static and Dynamic
    Lang M; Spektor AM; Hielscher T; Hoppner J; Glatting FM; Bicu F; Hackert T; Heger U; Pausch T; Gutjahr E; Rathke H; Giesel FL; Kratochwil C; Tjaden C; Haberkorn U; Röhrich M
    J Nucl Med; 2023 Feb; 64(2):244-251. PubMed ID: 35906094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous whole body (18)F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with (18)F-fluorodeoxyglucose positron emission tomography computed tomography.
    Pugmire BS; Guimaraes AR; Lim R; Friedmann AM; Huang M; Ebb D; Weinstein H; Catalano OA; Mahmood U; Catana C; Gee MS
    World J Radiol; 2016 Mar; 8(3):322-30. PubMed ID: 27028112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial.
    de Koster EJ; Vriens D; van Aken MO; Dijkhorst-Oei LT; Oyen WJG; Peeters RP; Schepers A; de Geus-Oei LF; van den Hout WB;
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3452-3469. PubMed ID: 35435497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
    Saito M; Ishihara T; Tada M; Tsuyuguchi T; Mikata R; Sakai Y; Tawada K; Sugiyama H; Kurosawa J; Otsuka M; Uchida Y; Uchiyama K; Miyazaki M; Yokosuka O
    Clin Gastroenterol Hepatol; 2013 Feb; 11(2):181-6. PubMed ID: 23142206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis.
    Schnitzer ML; Buchner J; Biechele G; Grawe F; Ingenerf M; von Münchhausen N; Kaiser CG; Kunz WG; Froelich MF; Schmid-Tannwald C; Rübenthaler J
    Eur J Radiol; 2023 Jun; 163():110803. PubMed ID: 37004464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.